CELINA WAKISAKA MARUTA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Dermatologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
- IgA pemphigus: Case series with emphasis on therapeutic response(2014) MORENO, Ana Carulina L.; SANTI, Claudia G.; GABBI, Tatiana V. B.; AOKI, Valeria; HASHIMOTO, Takashi; MARUTA, Celina W.
conferenceObject Lichen planus pemphigoides: Case reports and review of the literature(2012) HIRAYAMA, Andre; MARUTA, Celina; SANTI, Claudia; AOKI, ValeriaBackground: Lichen planus pemphigoides (LPP) is a rare autoimmune subepidermal blistering disease that shares clinical and/or immunopathologic features of lichen planus (LP) and bullous pemphigoid (BP). Epitope-spreading phenomenon may play a primordial role in the pathophysiology of this disease. LPP may represent a unique entity or a heterogeneous response to several basal membrane zone (BMZ) injuries, with exposure of different antigens leading to subepidermal blistering. Aim: To characterize two patients from Brazil that fulfilled the criteria for LPP, and to compare them with other reports in the literature. Methods: The diagnosis of LPP was confirmed by clinical, histologic, and immunologic (direct and indirect immunofluorescence, BP180 ELISA, immunoblotting) features. Results: The two patients evaluated in the study showed compatible clinical and laboratory findings of LPP, with lichenoid lesions coexisting with blisters because of the recognition of an autoimmune response against BP180. Conclusion: LPP could be either a single association between LP and BP, a unique condition, or part of a spectral autoimmune disease that recognize BMZ self-antigens. Possible triggersinclude BMZ aggressionsthat lead to an epitope spreading phenomenon.conferenceObject Comparative analysis of the in situ interleukin 23/T-helper 17 lymphocyte axis cytokine profile in IgA pemphigus, subcorneal pustular dermatosis, and pustular psoriasis(2014) SIGNORELLI, Thais Helena Dias; MARUTA, Celina Wakisaka; SANTI, Claudia Giuli; SOTTO, Mirian Nacagami; DIAS, Natasha Favoretto; ROMITI, Ricardo; AOKI, Valeria- Vulvo-cervico-vaginal manifestations and evaluation of Papanicolaou smears in pemphigus vulgaris and pemphigus foliaceus(2012) BARBOSA, Natasha D. Fairbanks; AGUIAR, Lana M. de; MARUTA, Celina W.; AOKI, Valeria; SOTTO, Miriam N.; LABINAS, Glaucia H. O.; PERIGO, Alexandre M.; SANTI, Claudia GiuliBackground: Vulvo-cervico-vaginal involvement has rarely been reported in pemphigus vulgaris (PV) and has not been reported in pemphigus foliaceus (PF). Objectives: We sought to evaluate genital lesions and Papanicolaou (Pap) smears in female patients with PV and PF. Methods: This prospective study includes all consecutive cases of female patients with PV and PF seen from May 2009 to February 2010. Gynecologic examination was performed and Pap smears were collected for cytologic analysis from each patient. Results: A total of 56 patients were given a diagnosis of pemphigus (41 PV and 15 PF). Genital involvement was observed in 9 patients with PV (22%) and the vulva was the most common genital site of involvement. Of these 9 patients, 8 presented with active skin/mucous lesions. Four of 15 patients with PF had genital lesions and vulva was the exclusive site of involvement. Three of 4 patients with PF and genital involvement also showed active cutaneous lesions. Six of 56 patients (5 PV and 1 PF) presented with atypical squamous cells of undetermined significance in Pap smear analysis. Upon further pathologic review, acantholytic cells were seen, confirming the diagnosis of pemphigus. Limitations: A small number of PF cases were studied. Conclusions: Vulvar lesions were the second most frequent site of mucous membrane PV. Herein we report the first case to our knowledge of symptomatic genital lesions in a patient with PF. Moreover, acantholytic cells in Pap smears were found in a patient with PF who was in complete remission off therapy with no clinical genital lesions and no circulating anti-desmoglein-1 and anti-desmoglein-3 autoantibodies. Gynecologic evaluation in patients with pemphigus, including a careful evaluation of Pap smears, should be recommended. (J Am Acad Dermatol 2012;67:409-16.)
conferenceObject Case report of bullous pemphigoid in infant(2017) WU, Isabelle I. Hue; RIVITTI-MACHADO, Maria Cecilia; MIYAMOTO, Denise; MARUTA, Celina; SANTI, Claudia Giuli; COSENZA, Fernanda DagirconferenceObject Increased vascular endothelial growth factor expression in erythrodermic pemphigus foliaceus patients(2016) MIYAMOTO, Denise; OTANI, Camila Sayuri Vicentini; FUKUMORI, Ligia Maria Ichimura; PEREIRA, Naiura Vieira; SOTTO, Mirian Nacagami; MARUTA, Celina Wakisaka; SANTI, Claudia Giuli; REBEIS, Marina Mattos; AOKI, ValeriaconferenceObject Mycophenolate mofetil as an adjuvant drug for the treatment of pemphigus vulgaris and pemphigus foliaceus(2012) LOUREIRO, Vivian Barzi; MARUTA, Celina; SANTI, Claudia Giuli; AOKI, ValeriaBackground: Pemphigus is a rare autoimunne bullous disease, characterized by blisters and erosions of the skin and/or mucous membranes. Its potentially life-threatening condition has been modified after the introduction of systemic corticosteroids. However, the long-term use of corticosteroids may lead to serious adverse effects. Mycophenolate mofetil has been used as a corticosteroid-sparing agent in the treatment of pemphigus. Objectives: To evaluate the effectiveness and safety of mycophenolate mofetil as adjuvant therapy in patients with pemphigus vulgaris and foliaceus. Methods: The study analyzed 23 patients diagnosed as pemphigus vulgaris (N = 17) or pemphigus foliaceus (N = 6), who had failed to previous treatments or experienced significant adverse effects with azathioprine, and were treated with mycophenolate mofetil. We also performed indirect immunofluorescence before andafter introduction of Mycophenolate Mofetil. Results: Remission wasachieved in 20 out of 23 patients (87%), and was characterized as follows: complete remission off therapy (N = 2), complete remission on minimal therapy (N = 6), partial remission on therapy (N = 6) and partial remission on minimal therapy (N = 6). Failure occurred in three out of 23 patients. Mycophenolate mofetil was well tolerated, once 20 out of 23 patients had no adverse effects. Conclusion: Mycophenolate mofetil has been demonstrated to be an effective and safe adjuvant drug in the treatment of pemphigus vulgaris and foliaceus, who had failed to previous treatments or experienced significant adverse effects with azathioprine.conferenceObject Epitope spreading in pemphigus patients from Sao Paulo, Brazil: A 10-year follow-up(2013) DELGADO, Livia; MARUTA, Celina W.; SANTI, Claudia G.; MYAMOTO, Denise; AOKI, ValeriaBackground: Pemphigus is a rare autoimmune blistering dermatosis. The shift from a disease to another is known as ‘‘epitope spreading’’ (ES). A primary inflammatory/autoimmune process releases ‘‘hidden’’ epitopes, and evokes a secondary reaction to antigens, distinct from and none cross-reactive with the target epitope. ES may be intra- or intermolecular. Objectives: The aim of the present study is to analyze the occurrence of ES within a 10-year interval in pemphigus patients followed-up at the Department of Dermatology, University of São Paulo, Brazil. Methods: Thestudy wascarried out in 351 pemphigus patients from January 2002 to January 2012. A careful search for clinical and laboratory changes suggestive of transition to a secondary bullous disease was performed, including clinical evaluation by at least 2 dermatologists. Laboratory profile (histopathology, direct-DIF and indirect-IIF immunofluorescence, and ELISA) was requested when suspicious skin lesions were detected. Results: Eight out of 351 pemphigus patients (153 pemphigus foliaceus-PF and 198 pemphigus vulgaris-PV) presented clinical transition: 7 from PV to PF (group 1) and 1 from PF to epidermolysis bullosa acquisita (EBA) (group 2). In group 1, median age at PVonset was 54 years and median interval of the disease shift was 3 years. Of the 7 patients with clinical PF, 4 showed change of pattern from suprabasilar cleavage to subcorneal acantholysis, 2 had cleavage within the middle epidermal layer, and 1 sustained the suprabasilar acantholysis. All patients showed intercellular IgG and C3 deposits during PVand PF diagnosis by DIF. IIF titers varied from 1:160 to 1:5120, and were positive during ES. ELISA index for Dsg1 varied from 1 to 319, and for Dsg3 from 0 to 290. Dsg1/Dsg3 indexes corresponded to the clinical PV-PF changes. In group 2, one patient switched from PF to EBA; onset of PF occurred at the age of 7, and ES to EBA 25 years later. Laboratory evaluation showed subepidermal cleavage with neutrophils, IgG intercellular staining in the epidermis and IgM, IgA, IgG and C3 deposits at BMZ by DIF, IgG deposits by indirect salt-split, recognition of collagen VII by immunoblotting, and positive ELISA for Dsg1. Conclusions: Intermolecular ES occurred in 2.2% of pemphigus patients. Futures studies will be necessary to elucidate the pathogenesis of this event and its significance in pemphigus progression.conferenceObject Mucocutaneous involvement in newborn with congenital epidermolysis bullosa acquisita(2016) CORREA, Paula Yume Sato Serzedello; MIYAMOTO, Denise; MARUTA, Celina Wakisaka; AOKI, Valeria; SANTI, Claudia GiuliconferenceObject Laryngeal involvement in paraneoplastic pemphigus associated with benign Brenner tumor(2016) ROCCHETTO, Helena; MIYAMOTO, Denise; AOKI, Valeria; MARUTA, Celina Wakisaka; SANTI, Claudia Giuli